Stockscreener 앱 받기
29.46
1.97%
0.57
시간 외 거래:
29.46
전일 마감가:
$28.89
열려 있는:
$29.47
하루 거래량:
600.04K
Relative Volume:
0.70
시가총액:
$1.44B
수익:
$109.79M
순이익/손실:
$-153.49M
주가수익비율:
-9.1781
EPS:
-3.2098
순현금흐름:
$-172.59M
1주 성능:
+4.25%
1개월 성능:
+22.19%
6개월 성능:
+0.14%
1년 성능:
+603.10%
1일 변동 폭
$29.28
$30.20
1주일 범위
$28.43
$30.51
52주 변동 폭
$3.605
$32.37
Urogen Pharma Ltd Stock (URGN) Company Profile
명칭
Urogen Pharma Ltd
전화
972 9 770 7601
주소
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
29.46 | 1.41B | 109.79M | -153.49M | -172.59M | -3.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Jefferies | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-06-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-19 | 재개 | Ladenburg Thalmann | Buy |
| 2024-08-22 | 개시 | Guggenheim | Buy |
| 2023-02-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-27 | 개시 | Berenberg | Buy |
| 2020-04-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-13 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | National Securities | Neutral |
| 2019-05-30 | 개시 | JP Morgan | Neutral |
| 2019-05-29 | 개시 | Goldman | Neutral |
| 2019-01-29 | 개시 | H.C. Wainwright | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-04-04 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-11-15 | 재확인 | Oppenheimer | Outperform |
| 2017-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
How UGN-103’s Phase 3 Data and NDA Timeline Could Reshape UroGen Pharma (URGN) Investors’ Outlook - simplywall.st
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge - AOL.com
How UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) Investors - Yahoo Finance
URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Sector Update: Health Care - Moomoo
UroGen Pharma Investor Event Reinforced Zusduri Commercial Thesis, Oppenheimer Says - marketscreener.com
Oppenheimer reiterates Outperform on UroGen Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates UroGen Pharma stock rating on durability data - Investing.com India
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA - GuruFocus
H.C. Wainwright reiterates UroGen Pharma stock rating on durability data By Investing.com - Investing.com South Africa
URGN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
UroGen Pharma Price Target Maintained With a $45.00/Share by HC Wainwright & Co. - Moomoo
A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data - simplywall.st
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story - simplywall.st
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC - Sahm
UroGen’s UGN-103 shows 94.5% response durability in trial By Investing.com - Investing.com Australia
Why (URGN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
UroGen Pharma (URGN) Reports Strong Results for UGN-103 in Bladd - GuruFocus
Paradigm reports 1.7M-share stake in UroGen (URGN) in 13G/A - Stock Titan
UroGen Moves Toward FDA Filing For UGN-103 - Citeline News & Insights
TD Bank subsidiary reports 2.62M UroGen shares (URGN) — 5.4% - Stock Titan
UroGen’s UGN-103 shows 94.5% response durability in trial - Investing.com UK
UroGen Reports 94.5% Six-Month Duration of Response in - GlobeNewswire
Bladder cancer drug posts 94.5% 6-month response, heads for 2026 FDA filing - Stock Titan
UroGen reports 64.5% event-free rate at three years for bladder cancer drug By Investing.com - Investing.com India
URGN: Caribou's allogeneic CAR T therapies show best-in-class potential with pivotal trials advancing - TradingView
UroGen Pharma (URGN) Reports Positive Long-Term Response Data fo - GuruFocus
UroGen Pharma Says ZUSDURI Shows Durable Disease-Free Outcomes at Three Years - Moomoo
UroGen reports 64.5% event-free rate at three years for bladder cancer drug - Investing.com
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial - The Manila Times
Urogen Pharma LtdReports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial - TradingView
ZUSDURI Median Duration of Response Still Not Reached with - GlobeNewswire
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $45 - 富途牛牛
MSN Money - MSN
Earnings call transcript: UroGen Pharma beats Q1 2026 EPS forecast - Investing.com India
Earnings call transcript: UroGen Pharma beats Q1 2026 EPS forecast By Investing.com - Investing.com Nigeria
UroGen Pharma stock (IL0011408896): CMO sells 10K shares at $30 - AD HOC NEWS
Urogen Pharma Ltd (URGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):